Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine Innovations Group (MYCO) partnered with the University of Alberta to launch a new AI drug discovery program that will make their research more efficient. The in-silico program uses machine learning and artificial intelligence to “rapidly screen hundreds of thousands of new molecules without the need to produce them, allowing Mydecine to focus on the strongest potential therapeutics”.